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The objective of this manuscript is to provide a description of the International Commission
for Radiation Protection (ICRP) model and a comparison to other models (the integrated
exposure uptake biokinetic [IEUBKI and O'Flaherty models), including the software used with
the models, and a comparison of the model predictions for selected situations. The ICRP
biokinetic model for Pb is a multicompartmental model for Pb uptake and disposition in
children and in adults. The model describes deposition and retention of absorbed Pb in
numerous tissues, removal from tissues to plasma, and movement along various routes of
excretion. Long-term skeletal behavior of Pb is described in terms of age-specific rates of
restructuring of compact and trabecular bone. The ICRP model is more flexible and has wider
applicability than the IEUBK model. The major disadvantages are that application of the
computer model requires some basic computer skills, and the user must convert the Pb
concentrations in food, air, soil, dust, paint, or other media to the amount of Pb ingested or
inhaled per day. Direct comparisons between the ICRP model and the IEUBK model are
provided by modeling blood Pb levels using the IEUBK vO.99d default Pb uptakes and intake
values. The model is used to simulate occupational exposure cases and a controlled Pb
inhalation experiment in adult humans. Finally, use of the model to explore situations with
limited data is illustrated by simulating the kinetics and disposition of Pb during acute Pb
poisoning and chelation therapy in a child. Environ Health Perspect 106(Suppl 6):1505-1511
(1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-6/1505-151 lpounds/abstract.html
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The populations and the exposure scenarios media for Pb exposure include air, food,
defining risk for Pb poisoning are exceed- soil, dust, paint chips, and many others.
ingly diverse. The fetus, infant, adolescent, Clearly, the data requirements to support
and adult in the workplace are at risk for risk assessment for these diverse exposure
Pb poisoning. Pb exposure may range from scenarios and populations at risk are enor-
low environmental levels to high levels mous. Physiologically based biokinetic
associated with leaded paint or occupa- models are effective tools for synthesizing
tional exposure. The exposure duration existing data, designing new research, sup-
may be chronic, acute, or intermittent. porting risk assessment decisions, and
The most important routes ofexposure are exploring real or hypothetical situations for
via inhalation, ingestion, or both. The which no data exist.
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Descriptionofthe ICRPModel
The International Commission on
Radiological Protection (ICRP) model is
the minimal system needed to synthesize a
wide variety of data from diverse studies
related to the biokinetics of Pb in humans
(Figure 1 ). These include studies of
healthy adult humans receiving Pb tracers
by injection, ingestion, or inhalation;
postmortem measurements of Pb in envi-
ronmentally exposed men, women, and
children; Pb balance studies conducted in
humans; and bioassay and autopsy mea-
surements on occupationally exposed sub-
jects. Data on the behavior ofPb in human
subjects were supplemented with findings
from Pb studies on laboratory animals at
different stages oflife and with experimen-
tal, occupational, environmental, and med-
ical data on the biokinetics ofelements with
physicochemical properties similar to those
of Pb. Finally, modeling of the long-term
retention of skeletal deposits of Pb was
based on age-dependent data on the rate of
bone restructuring, an approach that is sup-
ported by human and animal data on many
bone-seeking radionuclides (1).
The ICRP model describes the age- and
time-dependent distribution and excretion
of Pb injected directly into blood or
absorbed from the gastrointestinal tract
and/or lung. The schematic diagram ofthe
compartments used in the systemic model
and the directions ofPb movement among
compartments is shown in Figure 1. The
transfer rates between compartments and
the age-dependent physiologic parameters
are provided in Leggett (2). The transport
ofPb between compartments follows first-
order kinetics, provided the concentration
in the erythrocytes stays below a nonlinear
threshold concentration. A nonlinear
threshold concentration of 60 pg Pb/g red
blood cells (RBC), corresponding to about
25 pg Pb/dl whole blood, has been sug-
gested as a default value (2,3), but the
threshold level may vary substantially from
one person to another and may also
depend on the duration ofexposure.
Advantgs ofthe ICRPModel
The ICRP model has several distinct
differences, advantages, and disadvantages
compared with other biokinetic models for
Pb (Table 1). The advantages and disad-
vantages may vary in importance depend-
ing on the questions asked of the model
and the knowledge and experience of the
user. A particularly important advantage
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Figure 1. Structure of the ICRP biokinetic model for lead showing the compartments and direction of lead
movement between compartments. Modified from Leggett(2).
for many applications is that age-dependent
parameter values are provided for young,
middle-aged, and older adults as well as
for infants, children, and adolescents.
Thus, modeling is not restricted to chil-
dren but can include lifetime or occupa-
tional exposure scenarios. A second
important advantage is that the user has
versatile and nearly complete access to
almost all model input and output para-
meters. For example, the user is able to
redefine the default biokinetic and Pb
uptake parameters as required, as illus-
trated later in this paper. Other advan-
tages include the facile import of model
output into a spreadsheet or graphics soft-
ware for further analysis and presentation.
Finally, the source code is short and
is written in elementary FORTRAN,
and the computational steps within the
code are easy to follow. This allows the
nonprogrammer with knowledge of a few
basic FORTRAN commands to modify
the code for special applications. An
example ofcode modification to simulate
the biokinetics of Pb during chelation
treatment is provided in this report. Note
that the ease of altering the source code
by a nonprogrammer may also be consid-
ered a disadvantage, in that it can lead to
a proliferation ofslightly different source
codes developed for different applica-
tions. Also, the introduction of coding
errors is always a possibility, even for an
experienced programmer.
Disadvantages ofthe ICRPModel
The disadvantages of the model for
applications to Pb as a chemical toxicant
generally stem from the facts that a) the
model was designed primarily for use in
radiation protection, where the starting
point is often an intake level rather than
environmental concentration, and b) the
computer code was not originally intended
for dissemination to the public. For appli-
cations to Pb as a chemical toxicant, an
important disadvantage ofthe ICRP model
is that Pb input is defined in micrograms
per day to the gastrointestinal tract and to
the respiratory tract. Thus, the user must
convert the Pb concentrations in food, air,
soil, dust, paint, or other media to the
amount ofPb ingested or inhaled per day.
This conversion requires both effort and
judgment. This disadvantage may be rela-
tively unimportant when the Pb uptake is
experimentally defined or the situation is
hypothetical, but, depending on the user's
knowledge and experience, may be debili-
tatingforsite-specific blood-Pb modeling.
The ICRP model has other disadvan-
tages and differences from the integrated
exposure uptake biokinetic (IEUBK) and
O'Flaherty models. The ICRP program is
not menu driven but is run from a com-
mand line prompt using an input file
(described below). It does not incorporate a
statistical treatment to estimate population
values. It should be noted that the omission
ofan error estimate for population values is
not necessarily a disadvantage. Use ofgen-
eral U.S. population-based statistics to gen-
erate error estimates for a subpopulation
(that may have very different patterns ofPb
exposure and biokinetics) may provide an
inappropriate estimate for the subpopula-
tion. Finally, graphic display ofoutput is
not integrated into the program; output
data must be imported into a spreadsheet or
graphic software for futher analysis and
visual presentation.
Operationofthe ICRPModel
A 53-line, free-form ASCII input file is used
to provide the datastream (4). This input
file is prepared by the user with the aid of
any ASCII file editor. Lines 1 through 5
contain the computational parameters,
including the age at which modeling starts
and ends and the time-stepping for model
computation. Line 6 identifies five output
variables to be printed to an ASCII file.
Lines 7 through 12 are used to define the
intake scenario by selecting acute or chronic
exposure, the number of time periods with
different Pb intakes, and the daily Pb
intakes to the respiratory and gastrointesti-
nal tracts during these time periods. Lines
13 through 52 provide age-dependent trans-
fer rates and other model parameters that
are not normally changed by the user. Line
53 selects for chelation and defines the
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Table 1. Selected comparisons among biokinetic lead models.
Process IEUBK vD.99da O'Flahertyb ICRPC
Exposure Integrated into biokinetic Integrated, default levels None
module linked to historical levels
so that birth date may be
entered to define default
Absorption User-defined, multimedia User defined, age dependent, User defined,
Saturable and unsaturable but not media dependent age dependent
but not media dependent.
Excretion Sweat from softtissues Urine Sweat from plasma
GITfrom liver only GIT from plasma GITfrom liverand plasma
Urine from plasma only Lung to exhaled air Urine from kidney and plasma
Hair, skin, nails
Bone Four compartments; cortical and trabecular Two compartments; cortical and Six; cortical and trabecular bone are
bone are each characterized trabecular bone each characterized by surface,
by two compartments exchangeable, and nonexchangeable
compartments
Softtissues Three compartments; kidney, liver Four compartments; liver, kidney, poorly Other soft tissues, brain, GIT,
perfused tissues kidneys (2), lung, RBC, liver (2), soft
tissues (1, 2, and 3), well-perfused
tissues
Newborn PbB Starts as fraction of mother's Starts at 0 pg/dl Starts as fraction of mother's PbB
PbB(default 2.5pg/dl)
GIT, gastrointestinal tract. &From U.S. EPA sources (5,6). bFrom O'Flaherty (25-28). cFrom Leggett(2) and the FORTRAN source code.
duration and timing ofchelation treatment
with the chelation efficacy.
Applications
Comparison to IEUBKModel
The IEUBK model is the most commonly
used physiologically based pharmaco-
kinetic (PBPK) model for Pb in children.
To provide direct comparisons between
the IEUBK and the ICRP models, the
IEUBK daily Pb intake (micrograms Pb
per day taken into respiratory and gas-
trointestinal systems) or Pb uptake
(micrograms Pb per day absorbed into
blood) values for air, food, water, soil, and
dust (5,6) were used as input to the ICRP
model respiratory and gastrointestinal
uptake modules or directly into the blood
(Table 2). The default values were used
for all Pb absorption, distribution, and
other biokinetic parameters in both mod-
els. The mother's blood was set to 2.5
pg/dl for both models and the biokinetics
of Pb was simulated from birth to 7 years
of age. The ICRP model-predicted blood
lead (PbB) level at each age is approxi-
mately twice the IEUBK model-predicted
PbB value when IEUBK Pb uptake is used
to define the Pb input to the ICRP model
(Figure 2 and Table 3). The default
bioavailablity ofPb in water and diet is 50
and 30% for soil and dust in the IEUBK
model. The IEUBK model-predicted
absorption of the default Pb uptake is
between 32 and 35% (Table 2). The
default bioavailablity ofall gastrointestinal
Pb is 45% from birth to 1 year ofage and
30% to 5 years ofage in the ICRP model.
The daily uptake of Pb from the gastroin-
testinal and respiratory tracts was very sim-
ilar, except for the period from 6 to 12
months ofage (Figure 3). Thus, the differ-
ence in predicted PbB values is due mainly
to differences in the systemic biokinetics
Table 2. Age-dependent IEUBK v0.99d default values for lead intake and uptake.
Age, months
6-11 12-23 24-35 36-47 48-59 60-71 72-84
Default intake values, pg/day
Air 0.07 0.11 0.19 0.21 0.21 0.29 0.29
Diet 5.53 5.78 6.49 6.24 6.01 6.34 7.00
Drinking water 0.80 2.00 2.08 2.12 2.20 2.32 2.36
Soil 7.65 12.15 12.15 12.15 9.00 8.10 7.65
Dust 9.35 14.85 14.85 14.85 11.00 9.90 9.35
Paint 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Total intake 23.40 34.89 35.76 35.57 28.42 26.95 26.65
Default uptake values, pg/day
Diet 2.54 2.63 2.98 2.90 2.85 3.03 3.36
Water 0.37 0.91 0.96 0.99 1.04 1.11 1.132
Air 0.02 0.04 0.06 0.07 0.07 0.09 0.09
Soil + dust 4.68 7.36 7.44 7.53 5.69 5.16 4.89
Paint 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Total uptake, pg/day 7.59 10.90 11.38 11.42 9.58 9.30 9.3
Total uptake, % 32.4 31.2 31.8 32.00 33.7 35.1 35.2
IEUBK default bioavailability of ingested Pb(%): soil, 30; dust, 30; water, 50; diet, 50.
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Figure 2. Age-dependent ICRP model-predicted distri-
bution of Pb in blood and blood compartments using
the IEUBK default Pb intake values. Blood lead concen-
tration is pg Pb/dl; RBC concentration is pg Pb/g RBC;
plasma Pb content is given as total plasma Pb in micro-
grams and as percent Pb bound to plasma proteins.
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Table 3. Blood lead levels predicted by the IEUBK
v0.99d and ICRP models using the IEUBK default lead
exposure values.
Blood lead, pg/dl
Age, years IEUBKa ICRPa ICRPb
1 4.1 6.2 6.1
2 4.5 8.7 8.9
3 4.2 8.8 9.1
4 4.0 8.6 9.1
5 3.4 7.3 8.0
6 2.9 6.6 7.3
7 2.7 6.3 7.1
aModel-predicted PbB values using the IEUBK default
Pb intake (pg Pb/day to the gastrointestinal and respi-
ratory systems) values from Table 2. bModel-predicted
PbB values using the IEUBK default Pb uptake (pg Pb
absorbed into blood/day) values from Table 2. The
IEUBK default values are from the U.S. EPA Technical
Support Document(6). Parameters and equations used
in the IEUBK model (6) were used for both models.
Mother's PbB values setto 2.5for all runs.
of Pb in the two models. This conclusion
is supported by a second simulation using
the IEUBK Pb intake (micrograms Pb
absorbed into blood per day) to define the
Pb input to the ICRP model. This simula-
tion also gave ICRP-predicted PbB values
approximately twice the IEUBK-predicted
PbB values (Table 2).
SimulatedOccupational
LeadExposur
The kinetics ofPb in the human skeleton is
under investigation in several laboratories
using noninvasive X-ray fluorescence (XRF)
techniques. In particular, long-term XRF
studies on retired Pb workers has provided
information on the turnover rate of Pb in
bone (7-9). In these studies, the observed
turnover rate of bone Pb has varied with
the length ofthe follow-up period and the
bone selected for measurement. Based on
measurements ofPb in finger bone, a mean
half-time of 6.7 years was estimated for
subjects followed for 5 years after retire-
ment from Pb work, and a mean half-time
of 8.2 years was estimated for subjects fol-
lowed from year 7 to year 13 after retire-
ment (7). In retired workers followed for
over 18 years after the end ofexposure, the
asymptotic mean half-time of Pb in finger
bone was 16 years (8). In active and retired
Pb workers followed for many years, the
estimated mean half-times ofPb in the tibia
(largely cortical bone) and calcaneus (a mix-
ture of trabecular and cortical bone) were
27 years and 16 years, respectively (9).
Immediately after subjects were
removed from Pb work, PbB levels declined,
with a half-time of 30 to 40 days (7,8).
Descriptions of the long-term decline of
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PbB after retirement depended on the
number ofexponential terms used and the
length ofthe follow-up period, but eventu-
ally the decline in PbB roughly paralleled
that in the skeleton (7,8).
Only broad comparisons between these
data and model predictions can be made
because the precise time course and level of
exposure of the subjects to Pb are not
known, and model predictions vary some-
what with the assumed pattern and dura-
tion ofexposure. For presumably realistic
occupational exposure scenarios, however,
model predictions are consistent with the
findings ofthe XRF and PbB studies sum-
marized above. Model predictions for one
such scenario are shown in Figures 4 and 5.
For this scenario, occupational exposure
was assumed to begin at 20 years ofage and
end at 45 years of age (age of "retire-
ment"). Chronic Pb input to blood (micro-
grams per day) during occupational
exposure was arbitrarily adjusted to main-
tain PbB levels between 40 and 45 pg/dl,
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Figure 4. lifetime ICRP model-predicted concentration
of Pb in blood, cortical, and trabecular bone with simu-
lated 25-year occupational exposure to Pb beginning at
20 years of age and ceasing at age 45.
and input to blood from all external sources
after retirement was assumed to be 10
pg/day. For this scenario, the decline in
total skeletal Pb in the 15-year period after
retirement were best described by a bi-
exponential curve, with half-times ofabout
one and three decades. The loss ofPb from
the trabecular bone compartment was best
fit by a biexponential model wherein 23%
oftrabecular Pb was associated with a half-
time of 4 years and 77% was lost with a
half-time of22 years. The loss ofPb from
the cortical bone compartment was best
described by a monoexponential function,
with a half-time of34 years. The loss ofPb
from blood was best described by a tri-
exponential function in which 42% of
blood Pb was lost with a half-time of 57
days, 16% with a half-time of 1.3 years,
and the remainder with a half-time of24.4
years. The 1- and 25-year half-times are
consistent with the input ofsoft tissues and
the skeleton to the blood. These half-times
are also consistent with the half-times of
Pb in retired workers reviewed above.
Inves tion ofthePotential
Contribution ofBone Lead
to BloodLead
The ICRP model may be used to investigate
the importance oflong-term stores ofPb in
bone as a source ofblood Pb. In the com-
puter code used to implement the model,
the time-dependent flow rate into blood is
expressed as a sum offlow rates from sites of
absorption (respiratory and gastrointestinal
tracts) and from each of the internal com-
partments that feed blood, including the
two long-term storage compartments in
bone (nonexchangeable cortical and trabec-
ular bone volume). The calculation steps
through a series ofthousands ofshort time
Age, year
Figure 5. Lifetime ICRP model-predicted total Pb con-
tent of brain, kidney, liver, and soft tissues (pg Pb/tis-
suel with simulated 25-year occupational exposure to
Pb beginning at 20years of age and ceasing atage 45.
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periods oflength no greater than a few days,
and the average flow from each compart-
ment to blood is calculated over each
period. For a given exposure scenario, rela-
tive contributions ofPb to blood from gas-
trointestinal absorption, resorption of
cortical bone, resorption of trabecular
bone, and turnover of Pb in nonskeletal
tissues during each period can be isolated
and written to an output file.
Model simulations indicate that the
importance ofbone Pb as a source ofblood
level depends strongly on the assumptions
concerning the pattern and level of expo-
sure, fractional absorption of ingested or
inhaled Pb to blood, bone turnover rates,
and for high exposure levels, the nonlinear
threshold for uptake by RBC. The model
predicts that for persons exposed only to
gradually changing levels ofenvironmental
Pb and having typical rates of mobilization
from the skeleton as represented by the
baseline turnover rates, exogenous sources
are generally more important contributors
than bone stores to PbB. On the other
hand, model predictions indicate that long-
term stores ofPb in bone can be the domi-
nant source of PbB during the first few
years after removal from high, long-term
exposures such as those experienced by
many Pb workers, or in situations in which
there may be increased mobilization of
skeletal stores, such as in pregnant or
postmenopausal women.
As indicated in the preceding example,
retired Pb workers usually show a rapid
rate ofdecline of PbB soon after removal
from exposure, but the rate of decline
slows over a period ofmonths and eventu-
ally parallels that ofskeletal Pb (7,10-12).
In these subjects, PbB levels generally have
remained substantially higher than the
average background levels in a matched
population for at least a few years, suggest-
ing that bone Pb represents the dominant
source ofPbB in the retired workers during
this period. As in the preceding example,
only broad comparisons between these data
and model predictions can be made
because of inadequate information on the
time course and level of exposure of the
subjects before, during, and after occupa-
tional exposure, and the proper nonlinear
threshold (if any) to apply to these expo-
sures. However, for presumably realistic
occupational exposure scenarios, model
predictions are generally consistent with
the conclusion that bone Pb represents the
most important source of PbB for at least
a few years (Figures 4, 5) and sometimes
for several years after retirement.
Simulated Controlied LeadExposure
Griffin and co-workers (13) determined
changes with time in PbB levels in several
healthy adult male volunteers who were
exposed to elevated levels ofairborne Pb for
23 hr/day for about 18 weeks. The average
concentration of Pb in air in the exposure
chamber varied only slightly with time and
averaged 10.9 pg/m3 over the entire expo-
sure period. The mean PbB levels increased
to about 37 pg/dl during the exposure com-
pared with a mean of 20.4 pg/dl prior to
exposure. PbB levels returned to nearly nor-
mal levels about 2 months after the men
left the exposure chamber.
To simulate this controlled exposure,
input to blood (assumed to represent
primarily Pb absorbed from the gastroin-
testinal tract) was arbitrarily set at a con-
stant, chronic level such that PbB gradually
increased over several years (2000 days) to
the pre-exposure mean PbB value of 20.4
pg/dl. When this background PbB value
was attained, 58 pg/day was assigned to the
lungs over the next 125 days, based on a
concentration in air of 10.9 pg/m3, an air
intake rate of 15 m3/day, an intake time of
23 hr/day, and a lung deposition fraction
of 0.37 (2). Model predictions are
compared with observations in Figure 6.
Simulated ChelationTherapy
Metal-chelating drugs have been used for
many years for diagnosis ofmetal toxicity
and to enhance metal diuresis. The major
action ofchelators is to facilitate the transfer
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of Pb in blood to urine. Although several
studies have been conducted in laboratory
animals (14-16), little is known regarding
the tissue and cellular source of the Pb
excreted during chelation in children or in
adults (17-20).
Chelation is most simply modeled by
increasing the deposition fraction ofPb in
urine (default 0.015) and uniformly
decreasing the total transfer rate from
plasma to all other tissues, keeping the
total transfer rate from plasma to all desti-
nations at 2000/day. This approach is
illustrated and validated by a case report of
a Pb-poisoned child. The child lived in an
environment of uncharacterized Pb conta-
mination to 421 days of age. He then
moved to a home containing Pb paint in a
deteriorated condition. His blood Pb
reached 40 pg/day at about 1 150 days of
age and peaked at 57 pg/dl on day 1228.
He was treated with EDTA and BAL for 5
days as an inpatient and then released.
To simulate this exposure, daily Pb
intake was adjusted to give PbB levels
approximating 40 pg/dl, with a higher
intake for 2 months just before the chelation
(Figure 7). Chelation efficiency, defined in
the model as the fraction of the total out-
flow of Pb from plasma that is assigned to
the urinary bladder contents, was empiri-
cally set to 0.85 to provide the best fit to the
PbB measurements during the chelation
period. Table 4 and Figures 7 and 8 show
urinary Pb excretion and the ICRP model-
predicted Pb burden ofselected tissues.
100 150 200 250
Time after beginning of exposure, day
300 350
Figure 6. ICRP model-predicted and observed blood Pb levels in human volunteers exposed by inhalation to con-
trolled levels of Pb. Data are the observed PbB from Griffin et al. (13)(.) and the curve is ICRP model-predicted PbB.
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Table 4. Observed and ICRP model-predicted lead kinetics in a child during chelation therapy.
Time Observed urinary Pb, Predicted urinary Pb, Observed PbB Predicted PbB,
(age, days) pg/day pg/day pg/dl pg/dl
-14(1228) 65 57 56.7
1 (1252) 1754 480 46.4
2 (1253) 714 330 14 14.8
3 (1254) 1569 250 29.9
4(1255) 683 200 24.5
5(1256) 533 180 20.4
Total 1-5 days 5253 1450
14 (1261) 25 31.3
60 (1307) 30
)ata are the observed PbB (I) and the curve is Although model-predicted and observed
Jel-predicted PbBfrom birthto 5.5years ofage. PbB levels are comparable, it is apparent
that model-predicted and observed uri-
nary excretion of Pb during chelation are
not comparable. Even ifchelation efficacy
is set at 100%, the model significantly
underestimates the amount ofPb excreted
in urine. This discrepancy may be due in
Brain part to the omission from the chelation
model ofextracellular, nonplasma forms
Kidney of Pb that are labile to chelation. Exam-
*/ $ ' ples ofsuch labile Pb pools would include
Pb associated with the glycocalyx of ery-
PbB throcytes and tissue parenchymal cells, Pb
I 1 2 3 4 5 associated with extracellular matrix pro-
teins, and Pb associated with bone sur-
Age, year faces accessible to the plasmaborne
chelator. It is also conceivable that the
. ICRP model-predicted for blood and tissue Pb chelator has limited access to an intracel-
id PbB observations in a child receiving chela-
tmet fr bpisnin. ataar th osered lular Pb pool or to cells of a given pheno- ltment for Pb poisoning. Data are the observed
e .
nete of whc isicuddith and the curves are ICRP model-predicted PbB type, neither of which is included in the
Il nnd.Rnft tiI.Rrii Ph rnntpnt ltntiI tin Ph/ti, chelation model. py ulull allu ouil tl,-obUt U ill iutall LII i y UII/O-
sue) from birth to 5.5 years ofage.
This approach to modeling chelation is
adequate and appropriate if we assume
that the chelator modeled, 2,3-dimercapto-
succinic acid or EDTA, does not signifi-
cantly cross plasma membrane but merely
complexes and facilitates urinary excretion
of Pb as it appears in plasma. Predicted
decreases in PbB levels are reasonably
similar to observed decreases. In the
model, the decrease in tissue Pb is solely
dependent on the rate of Pb movement
from that tissue to the central compart-
ment, plasma. The model predicts little
decrease in the Pb content of tissues and
organs with a long Pb half-time (e.g.,
brain and bone) but a substantial decrease
in the Pb content of tissues and organs
with shorter Pb half-times (e.g., blood
and kidney).
ResearchNeedsforBiokineticModels
PBPK modeling is a powerful toxicologic
tool to convert exposure into target tissue
dose. Improvement in both model realism
and in our understanding of Pb toxicity
and kinetics is necessary for any of the
available models to achieve their full
potential for risk assessment. Needed
improvements include
* Refine models to accommodate lifetime
exposures by extending mathematical
descriptions ofage-dependent to 70
years ofage or more. This effort would
require information pertaining to bone
mineral metabolism, bone formation,
resorption, and bone mass, and Pb kinet-
ics associated with pregnancy and lacta-
tion, nutritional perturbation, aging, or
osteoporosis and other skeletal disease.
* Develop better data to validate the
target tissue dose response. That is,
blood is not the critical target tissue for
Pb poisoning. Thus, all models must
also be validated to the Pb content of
target tissues including brain and kidney
and other target tissues.
Models should be refined to accom-
modate gender, race, and ethnicity-
dependent differences in tissue mass
and skeletal dynamics and Pb kinetics.
Data should be developed describing
the biokinetics ofPb and the chelator-
Pb complex during chelation so that
models may more fully accommodate
chelation and some ofthe mysteries of
chelation (17) may be addressed.
Improved data for validation ofmodels
should be developed in humans with
low levels of Pb exposure. That is, all
of the Pb models have been con-
structed largely from data derived from
relatively high human Pb exposures,
resulting in very high PbB levels-
between 20 and 50 pg/dl. PbB levels of
concern have been reduced from 60 to
10 pg/dl in the last 30 years. There is a
paucity of data describing the age-
dependent absorption and biokinetics
ofPb for the "normal" U.S. population
with a PbB < 5 pg/dl. Lead models
should be recalibrated to appropriate
data for the lower Pb exposure levels
more common today and expected in
the future.
Skeletal Pb metabolism and kinetics is a
major component in the biokinetics of
Pb. Current models were developed
using skeletal Pb concentrations result-
ing from the higher Pb exposures com-
mon before the 1980s and 1990s. The
biokinetic models should be refined
using the wealth of human bone Pb
measurements made in recent years
using noninvasive technology ofX-ray
fluorescence (21-24).
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